Progyny (PGNY) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Anne Samuel maintained a Buy rating on Progyny (PGNYResearch Report) on August 8 and set a price target of $78.00. The company’s shares closed yesterday at $44.87.

Samuel covers the Technology sector, focusing on stocks such as Allscripts, Health Catalyst, and Convey Holding Parent. According to TipRanks, Samuel has an average return of 22.6% and a 53.33% success rate on recommended stocks.

Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $58.60, a 30.60% upside from current levels. In a report released on August 5, Jefferies also maintained a Buy rating on the stock with a $50.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $68.32 and a one-year low of $25.67. Currently, Progyny has an average volume of 892.5K.

Based on the recent corporate insider activity of 124 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PGNY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.

Read More on PGNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More